Lastest Stories by Trey Thoelcke

Here is an assessment of how safe the dividend at AbbVie appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe the dividend at Abbott Laboratories appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe PepsiCo's dividend appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe Walmart's dividend appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe the dividend at Walgreens appears to be after last year's cut, based on a variety of metrics.
Here is an assessment of how safe Altria’s generous dividend appears to be based on a variety of metrics.
Here is an assessment of how safe Exxon Mobil’s dividend appears to be based on a variety of metrics.
Insider buying was somewhat slow in the middle of January, but some purchases by Warren Buffett's Berkshire Hathaway made headlines.
Here is an assessment of how safe IBM’s dividend appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
As the year got underway, biotechs were in focus among the notable insider buying, especially in two companies focused on treatments for the eye.
Here is an assessment of how safe Procter & Gamble’s dividend appears to be based on a variety of metrics.
Here is an assessment of how safe Ford’s dividend appears to be based on a variety of metrics.
Here is an assessment of how safe Verizon’s dividend appears to be based on a variety of metrics.
Here is an assessment of how safe McDonald’s dividend appears to be based on a variety of metrics.
Here is an assessment of how safe 3M’s dividend appears to be based on a variety of metrics. Is 3M about to lose its status as a Dividend King?
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.